Felixvet Strengthens Leadership Team with Lauren Landolph as VP, Head of Commercial & Distribution

Kansas City, Mo. — July 16, 2025 — Felixvet, Inc., is pleased to announce that Lauren Landolph has joined the company as VP, Head of Commercial & Distribution Channel. In this role, Landolph will lead Felixvet’s U.S. commercial strategy, overseeing sales execution, e-commerce and distribution partnerships, as well as supporting the continued growth of Felixvet’s expanding veterinary pharmaceutical portfolio.

Landolph brings nearly two decades of experience across the animal and human health industries, with a proven track record of launching innovative products, scaling commercial organizations and accelerating market growth. Her previous role was associate vice president and head of commercial at ZyVet Animal Health, a division of Zydus Pharmaceuticals, where she led the successful launch and rapid expansion of its U.S. animal health business.

She has held leadership positions in both startups and global pharmaceutical companies, including Zolutia, Veterinarian Recommended Solutions (VRS) and Abbott Animal Health. Additionally, her commercial roles at GlaxoSmithKline, Pfizer and Allergan have provided her with extensive experience across various therapeutic areas and healthcare channels.

“Lauren is widely respected for her collaborative leadership style, deep industry insight and ability to deliver results in complex markets,” said Vince Palasota, president of Felixvet North America. “Lauren is a key addition to the Felixvet team as the company enters its next phase of growth.”

Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We’ve built a strong foundation with a clear vision for the future of animal health,” said Neeraj Agrawal, managing director and founder of Felix. “We’re excited to welcome Lauren at this pivotal time as we scale our commercial and distribution strategy in the generic and value-added bioequivalent space. Our people set us apart, and we are committed to investing in the best in all aspects of our business to drive sustainable growth and deliver lasting value to our stakeholders.”

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com